This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00743/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/mesh/concept/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00743/identifier/drugbank/
n7http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00743/identifier/national-drug-code-directory/
n12http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00743/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/patent/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00743/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00743/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00743
rdf:type
n3:Drug
n3:description
Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.
n3:dosage
n19:271B55AB-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L: Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S161-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608412 # Morana G, Salviato E, Guarise A: Contrast agents for hepatic MRI. Cancer Imaging. 2007 Oct 1;7 Spec No A:S24-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17921081 # Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J: Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol. 1992 Apr;158(4):887-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1546612 # Kirchin MA, Pirovano GP, Spinazzi A: Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998 Nov;33(11):798-809. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9818314 # Clement O, Siauve N, Cuenod CA, Vuillemin-Bodaghi V, Leconte I, Frija G: Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608397
n3:group
approved
n3:halfLife
1 hour
n3:indication
Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
n3:manufacturer
n7:271B55A9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00743 n12:DB00743
dcterms:title
Gadobenate Dimeglumine
adms:identifier
n5:PA164745426 n16:6918204 n18:46506805 n20:0270-5164-12 n21:170831 n22:DB00743
n3:mechanismOfAction
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gadobenate Dimeglumine shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gadobenate Dimeglumine primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadobenate Dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
n3:packager
n7:271B55A6-363D-11E5-9242-09173F13E4C5 n7:271B55A7-363D-11E5-9242-09173F13E4C5 n7:271B55A8-363D-11E5-9242-09173F13E4C5
n3:patent
n23:4916246
n3:routeOfElimination
Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine.
n3:synonym
Gadobensäure Acidum gadobenicum Gadobenic acid Multihance Acido gadobenico Acide gadobenique Gadobenate dimeglumine
n3:toxicity
Gadolinium-based radiocontrast agents like gadobenate dimeglumine are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
n10:hasAHFSCode
n24:92-00-00
n3:proteinBinding
Plasma protein binding is low, weak, and transient.
n3:synthesisReference
Pier Lucio Anelli, Pierfrancesco Morisini, Silvia Ceragioli, Fulvio Uggeri, Luciano Lattuada, Roberta Fretta, Aurelia Ferrigato, "Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form." U.S. Patent US20120232151, issued September 13, 2012.
n14:hasConcept
n15:M0324761
n3:IUPAC-Name
n6:271B55AD-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B55B3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B55B2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B55AF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B55B0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B55B1-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B55AC-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:V08CA08
n3:H-Bond-Acceptor-Count
n6:271B55B9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B55BA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B55B4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B55B5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B55B7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B55B6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B55B8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
113662-23-0
n3:category
n3:clearance
* 0.093 +/- 0.010 L/hr/kg [healthy male subjects receiving 3 single-dose IV administration with doses from 0.005-0.4 mmol/kg]
n3:containedIn
n17:271B55AA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B55BF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B55C1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B55C2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B55BE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B55BD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B55C0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B55AE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B55BB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B55BC-363D-11E5-9242-09173F13E4C5